The Effect of Red-Yeast-Rice Supplement on Serum Lipid Profile and Glucose Control in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance |
Kang, Mi-Ran
(Interdisciplinary Program: Science for Aging, Yonsei University)
Kim, Ji-Young (National Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University) Hyun, Yae-Jung (National Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University) Kim, Hyae-Jin (National Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University) Yeo, Hyun-Yang (Interdisciplinary Program: Science for Aging, Yonsei University) Song, Young-Duk (Department of Endocrinology and Metabolism, NHIC Ilsan Hospital) Lee, Jong-Ho (National Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University) |
1 | Pontrelli L. et al. Atorvastatin treatment beneficially alters the lipoprotein profile and increses low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002; 51(3): 334-342 DOI ScienceOn |
2 | Chang JC, Wu MC, Liu IM, Cheng JT. Plasma glucose-lowering action of Hon-Chi in Streptozotocin-induced diabetes rats. Horm Metab Res 2006; 38(2): 76-81 DOI ScienceOn |
3 | Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004; 58(10): 614-618 DOI ScienceOn |
4 | Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290(4): 486-494 DOI ScienceOn |
5 | Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietaty Chinese red-yeastrice dietary supplement. Am J Clin Nutr 1999; 69: 231-236 DOI |
6 | Choi YS, Lee SY. Serum cholesterol and 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Korean Soc Food Sci Nutr 1992; 21(5): 580-593 |
7 | Patrick L, Uzick M. Cardiovascular Disease; C-reactive protein and the inflammatory Disease Paradigm: HMG-CoA reductase, Red yeast rice and Olive oil polyphenols. Altern Med Rev 2001; 6(3): 248-271 |
8 | Yang HT, Lin SH, Huang SY, Chou HJ. A comparative Study of Xuezhikang and Mevalotin in treatment of Essential Hyperlipidemia. Chinese Journal of New Drugs 1997; 6: 265-268 |
9 | Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis risk in communities study): a cohort study. Lancet 1999; 353: 1649-1652 DOI ScienceOn |
10 | Satoh K, Keimatsu N, Kanda M, Kasai T, Takaguri A, Sun F, Ichihara K. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biol Pharm Bull 2005; 28(11): 2092-2095 DOI ScienceOn |
11 | Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, Varricchio M. Effects of simvastatin and atovastatin administration in insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000; 150(1): 121-127 DOI ScienceOn |
12 | King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431 DOI ScienceOn |
13 | Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200 DOI ScienceOn |
14 | Kuno N, Mizutani T. A Clinacal Study on treating Primary Hyperlipidemia with Xuezhikang. Chinese Circulation J 1997; 12: 16-19 |
15 | Kawai T, Tokui M, Funae O, Meguro S, Yamada S, Tabata M, Shimada A. Efficacy of pitavastatin, a New HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care 2005;28(12): 2980-2981 |
16 | www.nso.go.kr |
17 | Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the U. S.: 1990-1998. Diabetes Care 2000; 23: 1278-1283 DOI ScienceOn |
18 | Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103(3): 357-362 DOI |
19 | Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: the inter99 study. Diabetes Care 2003; 26: 2335-2340 DOI ScienceOn |
20 | Farrer M, Winocour PH, Evans K, Neil HA, Laker MF, Kesteven P, Alberti KG. Simvastatin in non-insulin dependent diabetes mellitus: effect on serum lipid, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994; 23: 111-119 |
21 | http://www.krra.or.kr |
22 | Wang J, Lu Z, Chi J, Wang W, Su M, Kou W, Y'u L, Chen L, Zhu JS, Chang J. Multicenter clinical trial of the serum lipidlowering effects of a Monascus purpureus (red yeast) rice preparation from traditional chinese medicine. Curr Ther Res Clin Exp 1997; 58: 964-977 DOI ScienceOn |
23 | Bell PM. Clinical significance of insulin resistance. Diabet Med 1996; 13: 504-509 DOI ScienceOn |
24 | Liu L, Zhao SP, Cheng YC, Li YL. Xuezhikang Decreases Serum Lipoprotein (a) and C-reactive Protein Concentrations in patients with Coronary Heart Disease. Clin Chem 2003; 49: 1347-1352 DOI ScienceOn |
25 | Reaven GM. Insulin resistance, Hyperinsulinemia, Hypertriglyceridemia and hypertension: parallels between human disease and rodent models. Diabetes Care 1991; 14: 195-202 DOI ScienceOn |